Oncology portal registers over 12,000

Share this article:
Elsevier's OncologySTAT portal has attracted over 12,000 registrants since its September 2007 launch. Seventy percent are physicians or healthcare professionals involved in cancer care, according to company data.

The site garnered a top search ranking on Google, and that's enabled advertising abilities, said Monique Fayad, SVP, Elsevier, and publisher of OncologySTAT. 

“Our Google rankings are new —we were in the sandbox for the first six months,” said Fayad, referring to the sandbox effect, by which new URLs tend to receive lower-page rankings on Google either by company policy or mathematical algorithm. “Coming out [of the sandbox], we were on the first page of search results. This hasn't had a direct impact on sales yet, but we expect it will very soon.”

Since September, Oncology-STAT has optimized the site for better searching, updated and enhanced its video player, and has shifted toward a greater focus on content drivers. 

“We're gaining the critical mass we'd hoped for—we have the audience now, so we can focus on new features,” noted Fayad. In terms of targeting, Fayad said the portal's core target audience is oncology and hematology professionals. “Our goal is to get 40% [of practicing US hematologists and oncologists], and we're 22% of the way there,” said Fayad.

Fayad cited OncologySTAT's coverage of the American Society of Clinical Oncology annual conference last June as a success. The portal's 10-member advisory board made recommendations about “must see” sessions during the conference, resulting in great feedback, according to Fayad. 

At an Oncology Nurses Society meeting, OncologySTAT was well-received and signed up 500 nurses in two days, said Fayad, with 700 new registrants in three days. Portals in different therapeutic classes could follow. “We're currently evaluating other [potential portals] based on OncologySTAT,” said Fayad. 
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...